In a report released yesterday, Matthew Bouley from Barclays maintained a Buy rating on DR Horton (DHI), with a price target of $41. The company’s shares closed yesterday at $34.22, close to its 52-week low of $33.70.
According to TipRanks.com, Bouley is ranked 0 out of 5 stars with an average return of -10.0% and a 37.0% success rate. Bouley covers the Industrial Goods sector, focusing on stocks such as Builders Firstsource, BMC Stock Holdings, and JELD-WEN Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DR Horton with a $48.67 average price target, implying a 42.2% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $40 price target.
.
See today’s analyst top recommended stocks >>
Based on DR Horton’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $454 million. In comparison, last year the company had a net profit of $313 million.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Michael Hewatt, a Director at DHI sold 3,000 shares for a total of $135,030.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
D.R. Horton, Inc. operates as a national homebuilder that engages in the construction and sale of single-family housing. It operates through the Homebuilding and Financial Services segments. The Homebuilding segment includes the sub-segments East, Midwest, Southeast, South Central, Southwest, and West regions.
